This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Madrigal Pharmaceuticals, Inc.
Drug Names(s): STA-9090
Description: STA-9090 is a novel, injectable, synthetic, small-molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a chaperone protein that regulates the activity of numerous signaling proteins, in particular kinase proteins, that trigger uncontrolled proliferation in cancer cells. STA-9090 was developed internally by Synta using the Company's internal chemistry and drug optimization expertise to invent a novel chemical structure unrelated to the ansamycin family of Hsp90 inhibitors such as 17-AAG.
Additional information available to subscribers only: